We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Heart Attack Warning Sign Discovered

By HospiMedica International staff writers
Posted on 19 Jan 2011
A new study has found that elevated blood levels of the cleaved p17 fragment of the caspase-3 peptide (p17)--the end effector caspase for apoptosis--can serve as a predictor of acute myocardial infarct (AMI).

Researchers at the University of Connecticut (Storrs, USA) studied 27 consecutive patients undergoing primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with a door-to-balloon time of less than 90 minutes, between December 2007 and January 2010. More...
The researchers measured p17 levels at least twice 8 hours apart during the initial 24 hours, and the peak level was determined as the higher of the AMI values. Cardiac troponin I (cTnI) and creatine kinase (CK) levels were determined every 8 hours for 24 to 36 hours, with the 99th percentile value as the upper limit.

The researchers found that peak serum p17 peptide level during AMI was higher than the late post-MI serum level in 21 subjects in whom samples were available during both phases. Compared with healthy subjects, the peak AMI p17 level was nearly 4-fold higher than that in healthy subjects; the late post-MI p17 peptide level was also higher than that of healthy subjects, consistent with persistent apoptosis after AMI. In all subjects, the peak p17 peptide level occurred after PCI and was positively correlated with the peak cTnI and and peak CK levels. The researchers suggest that rise and fall of p17 peptide and its correlation with peak cTnI and CK suggest that serum p17 likely came from injured myocardium. The study was published in the January 11, 2011, issue of the Journal of the American College of Cardiology.

"We've discovered a new biomarker for heart attack, and showed that apoptosis, or a particular kind of cell death, is a cause of heart muscle damage,” said lead author Bruce Liang. "The ability to see a heart attack coming with a simple blood test and to develop new therapies to block apoptosis would enable us to get a head start on treatment and preserve crucial heart muscle and cardiac function.”

Related Links:

University of Connecticut



Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.